[email protected]   +1 (304) 306-0723

TIGIT Inhibitors – Market Opportunity, Pipeline & Competitive Intelligence 2020

$3,950.00$11,850.00

This TIGIT report covers the TIGIT market opportunity providing Key Competitive Analysis, 15+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc), Licensing and Agreements, Business Agreement, business partner, Clinical Agreement, 2020 Earnings call update, Market launch preparation, Marketing Strategy, Future agenda and Upcoming events.

Clear
SKU: MM202018 Categories: , , Tag:

Description

The T cell immunoglobulin checkpoint and ITIM domain (TIGIT) has gained a lot of attention in recent years due to the number of roles it plays in different malignant tumors. It is also called WUCAM, Vstm3, VSIG9 and interacts with CD155 expressed on antigen presenting cells or tumor cells to downregulate the functions of T and natural killer (NK) cells.

TIGIT has emerged as a key inhibitor of anti-tumor responses that can hinder multiple stages of the cancer immune cycle. The precise mechanism of action remains unclear and may have both cell-intrinsic and cell-extrinsic components; it can, for example, prevent NK from releasing tumor antigens cells, alter the priming of T cells by DCs or inhibit the killing of cancer cells by CD8+ T cells. The expression of TIGIT frequently occurs in parallel with the expression of other co-inhibitory receptors, in particular PD-1, where it acts synergistically to regulate the antitumor response.

The diverse function of TIGIT in multiple cell types has made it a profitable candidate for immunotherapy, with an increasing number of candidates being studied in preclinical and clinical settings. Preclinical studies have indicated that TIGIT blockade can protect against various solid and hematological cancers. Several monoclonal antibodies (mAbs) have been developed that block the inhibitory activity of human TIGIT. Studies combining antibodies against TIGIT with ICI of the PD-1 / PD-L1 pathway have become particularly interesting in light of the data showing the co-expression of TIGIT and PD-L1 in many types of cancer. Clinical trials are underway studying TIGIT blockade alone or in combination with PD1 / PD-L1 antibodies for the treatment of patients with advanced solid tumors.

The mechanism has piqued the interest from Merck and Roche, with the latter having the most advanced candidate, tiragolumab. There are more than 15 companies exploring their candidates. This report covers the TIGIT Market Opportunities by providing Key Competitive Analysis, 15+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc), Licensing and Agreements, Business Agreement, business partner, Clinical Agreement, 2020 earnings call update, market launch preparation, marketing strategy, future agenda and upcoming events.

Key Takeaways from the Report

  • Indication Prioritisation: TIGIT market potential based on Indications
  • Business Transactions & Strategies: Key collaborations and deal values
  • TIGIT Pipeline Development: Product Profiles, Clinical Trials & Results
  • TIGIT Acquisition Targets
  • TIGIT Competitive Intelligence
  • Recent & Upcoming events

Table of Contents

  1. OVERVIEW
  2. KEY TAKEAWAYS
  3. The TIGIT Target BACKGROUND
  4. Indication Prioritization
    • TIGIT market potential based on Indications
    • TIGIT in cancer immunotherapy
  5. TIGIT LICENSING AND COLLABORATION DEALS
    • TIGIT Licensing Details and Deal values
    • TIGIT Acquisition Details & Deal Values
  6. TIGIT PIPELINE LANDSCAPE
    • TIGIT Pipeline Analysis
    • TIGIT Clinical Trial Landscape
  7. TIGIT Competitive Intelligence
    • Product Positioning
    • Product Goals
    • Launch Strategies
  8. TIGIT PIPELINE DRUG PROFILES & CLINICAL TRIAL ANALYSIS
    • Genentech/Roche: Tiragolumab
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments 
    • Arcus Bioscience: AB154
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments 
    • Merck: MK‐7684
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments 
    • Bristol‐Myers Squibb: BMS‐986207
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments 
    • Mereo Biopharma: Etigilimab
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments 
    • Astellas Pharma / Potenza Therapeutics: ASP8374
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments 
    • Iteos Therapeutics: EOS-448
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments 
    • Compugen: COM-902
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments 
    • List of drugs continued….
  9. UPCOMING EVENTS
  10. Appendix

Companies Covered

  1. Roche
  2. Merck & Co
  3. Bristol-Myers Squibb
  4. Potenza Therapeutics
  5. Astellas Pharma
  6. Arcus Biosciences
  7. Beigene
  8. Mereo Biopharma
  9. Compugen
  10. Innovent
  11. Iteos Therapeutics
  12. Agenus
  13. Seattle Genetics
  14. Others
Name
Email
Phone
Enquiry

Get In Touch

Let's keep the conversation going